Author

Kyle Kitchen

Institution: Utah Cancer Specialists

Observed institution: Utah Cancer Specialists

ORCID: 0000-0002-1212-9894

Observed ORCID: 0000-0002-1212-9894

OpenAlex ID: A5083765780

Real-world febrile neutropenia rates with same-day versus next-day pegfilgrastim after myelosuppressive chemotherapy

2022 · Kyle Kitchen, Michael C Mosier · Future Oncology · 8

Optimizing Clinical Trial Subject Selection: Insights from Exigent Research Network and the Tempus AI TIME Program Collaboration

2024 · Samantha Mallahan, Ajeet Gajra, et al. · AI in Precision Oncology · 5

Real-world comparison of febrile neutropenia rates with same-day versus next-day administration of pegfilgrastim.

2021 · Kyle Kitchen, Michael C. Mosier · Journal of Clinical Oncology · 3

Impact of Exigent Research Network’s partnership with the Tempus AI TIME Program on the screening and matching of patients for clinical trials.

2024 · Ajeet Gajra, Samantha Mallahan, et al. · Journal of Clinical Oncology · 1

Building a system to ensure awareness of nirogacestat, a treatment for desmoid tumors

2026 · Kyle Kitchen · The American Journal of Managed Care

Quality initiative in first-line chronic lymphocytic leukemia /small lymphocytic lymphoma assessing the use of 2nd generation BTKi therapy and impact on cardiac medical conditions patients experience on treatment

2025 · Jing-Zhou Hou, Tejvir Singh, et al. · Blood

Works count: 6

Citation count: 17

H-index: 3

I10-index: